The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis

American Journal of Obstetrics and Gynecology

Volumn 217, Issue 2, 2017, Pages 150-166

  Verkaik, Saskia ^d   Kamperman, Astrid M ^a,b   van Westrhenen, Roos ^b   Schulte, Peter F J ^c  

^a Epidemiological and Social Psychiatric Research Institute   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Treatment Centre for Bipolar Disorders   (Netherlands)

^d NONE

Author keywords

meta analysis; premenstrual syndrome; systematic review; Vitex agnus castus

Indexed keywords

VITEX AGNUS CASTUS EXTRACT; PLANT EXTRACT;

ADVERSE OUTCOME; DATA EXTRACTION; DRUG EFFICACY; DRUG SYNTHESIS; DRUG TOLERABILITY; FEMALE; HUMAN; META ANALYSIS; PATIENT SATISFACTION; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PUBLISHING; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; VITEX AGNUS CASTUS; PHYTOTHERAPY; VITEX;

FEMALE; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; PREMENSTRUAL SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITEX;

EID: 85017191256     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2017.02.028     Document Type: Review

References (64)

1. O'Brien, S., Rapkin, A., Dennerstein, L., Nevatte, T., Diagnosis and management of premenstrual disorders. BMJ, 342, 2011, d2944.
2. Yonkers, K.A., O'Brien, P.M., Eriksson, E., Premenstrual syndrome. Lancet 371 (2008), 1200–1210.
3. Beers, M.H., Porter, R.S., Jones, T.V., Kaplan, J.L., Berkwits, M., Merck manual of diagnosis and therapy. 18th ed., 2006, Merck Research Laboratories, Whitehouse Station (NJ).
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed., 2013, American Psychiatric Publishing, Arlington (VA).
5. Association of Reproductive Health Professionals. A quick reference guide for clinicians. Managing premenstrual symptoms. Available at: http://www.arhp.org/uploadDocs/QRGPMS.pdf. Accessed Feb. 18, 2013.
6. Parry, B.L., Berga, S.L., Mostofi, N., Klauber, M.R., Resnick, A., Plasma melatonin circadian rhythms during the menstrual cycle and after light therapy in premenstrual dysphoric disorder and normal control subjects. J Biol Rhythms 12 (1997), 47–64.
7. Shechter, A., Lespérance, P., Ng Ying Kin, N.M., Boivin, D.B., Pilot investigation of the circadian plasma melatonin rhythm across the menstrual cycle in a small group of women with premenstrual dysphoric disorder. PLoS One, 7, 2012, e51929.
8. Baller, E.B., Wei, S.M., Kohn, P.D., et al. Abnormalities of dorsolateral prefrontal function in women with premenstrual dysphoric disorder: a multimodal neuroimaging study. Am J Psychiatry 170 (2013), 305–314.
9. Wang, A.C., Hara, Y., Janssen, J.G., Rapp, P.R., Morrison, J.H., Synaptic estrogen receptor-alpha-levels in prefrontal cortex in female rhesus monkeys and their correlation with cognitive performance. J Neurosci 30 (2010), 12770–12776.
10. Montague, D., Weickert, C.S., Tomaskovic-Crook, E., Rothmond, D.A., Kleinman, J.E., Rubinow, D.R., Estrogen receptor alpha localization in the prefrontal cortex of three mammalian species. J Neuroendocrinol 20 (2008), 893–903.
11. Freeman, E.W., Rickels, K., Characteristics of placebo responses in medical treatment of premenstrual syndrome. Am J Psychiatry 156 (1999), 1403–1408.
12. European Medicines Agency. Guidelines on the treatment of PMDD. London. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500110103.pdf. Accessed Feb. 18, 2013.
13. Royal College of Obstetricians and Gynecologists. Management of premenstrual syndrome. RCOG green-top guideline no. 48, 2016. Available at: http://www.rcog.org.uk/womens-health/clinical-guidance/management-premenstrual-syndrome-green-top-48. Accessed Jan. 13, 2017.
14. Shah, N.R., Jones, J.B., Aperi, J., Shemtov, R., Karne, A., Borenstein, J., Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol 111 (2008), 1175–1182.
15. Andrade, C., Sharma, E., Serotonin reuptake inhibitors and risk of abnormal bleeding. Psychiatr Clin North Am 39 (2016), 413–426.
16. Whelan, A.M., Jurgens, T.M., Naylor, H., Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol 16 (2009), e407–e429.
17. Blumenthal, M., Goldberg, A., Brinckmann, J., Herbal medicine, expanded commission E monographs. Am Botanical Counc Integrative Med Commun, 2000, 62–64 http://cms.herbalgram.org/expandedE/?ts=1490716907&signature=d59ae01eb534534a3fa215c0e75b9472. Accessed March 28, 2017.
18. Wuttke, W., Jarry, H., Christoffel, V., Spengler, B., Seidlová-Wuttke, D., Chaste tree (Vitex agnus-castus)–pharmacology and clinical indications. Phytomedicine 10 (2003), 348–357.
19. Webster, D.E., He, Y., Chen, S.N., Pauli, G.F., Farnsworth, N.R., Wang, Z.J., Opioidergic mechanisms underlying the actions of Vitex agnus-castus L. Biochem Pharmacol 81 (2011), 170–177.
20. Jarry, H., Spengler, B., Porzel, A., Schmidt, J., Wuttke, W., Christoffel, V., Evidence for estrogen receptor beta-selective activity of Vitex agnus-castus and isolated flavones. Planta Med 69 (2003), 945–947.
21. EMA. Community herbal monograph on Vitex agnus-castus L, fructus. London. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_Community_herbal_monograph/2011/01/WC500101541.pdf. Accessed Feb. 29, 2013.
22. Dante, G., Facchinetti, F., Herbal treatments for alleviating premenstrual symptoms: a systemic review. J Psychosom Obstet Gynaecol 32 (2011), 42–51.
23. Van Die, M.D., Burger, H.G., Teede, H.J., Bone, K.M., Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials. Planta Med 79 (2013), 562–575.
24. Shaw S, Wyatt K, Campbell J, Ernst E, Thompson-Coon J. Vitex agnus castus for premenstrual syndrome (protocol). Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No: CD004632. http://dx.doi.org/10.1002/14651858.CD004632.
25. Handbook for systematic reviews of interventions. Version 5.1.0. Cochrane Collaboration; 2011. Available at: http://handbook.cochrane.org. Accessed March 28, 2017.
26. Egger, M., Davey Smith, G., Altman, D.G., Systematic reviews in health care: meta-analysis in context. 2nd ed, 2001, BMJ Publishing Group, London.
27. Borenstein, M., Hedges, L., Higgins, J., Rothstein, H., Comprehensive meta-analysis. Version 3.3.070. 2005, Biostat, Englewood (NJ).
28. Steiner, M., Haskett, R.F., Carroll, B.J., Premenstrual tension syndrome: the development of research diagnostic criteria and new rating scales. Acta Psychiatr Scand 62 (1980), 177–190.
29. Moos, R.H., The development of a menstrual distress questionnaire. Psychosom Med 30 (1968), 853–867.
30. Mortola, J.F., Girton, L., Beck, L., Yen, S.S., Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. Obstet Gynecol 76 (1990), 302–307.
31. EndNote X6. 1988-2012. Version X6. London: Thomsom Reuters Scientific. www.endnote.com.
32. Cohen, J., A coefficient for agreement for nominal scales. Educ Psychol Meas 20 (1960), 37–46.
33. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 2009, e1000097.
34. Liberati, A., Altman, D.G., Tetzlaff, J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ, 339, 2009, b2700.
35. Harris, R.J., Bradburn, M.J., Deeks, J.J., Harbord, R.M., Altman, D.G., Sterne, J.A.C., Metan: fixed- and random-effects meta-analysis. Stata J 8 (2008), 3–28.
36. StataCorp. Stata: Release 13, 2013, StataCorp LP, College Station (TX).
37. Atmaca, M., Kumru, S., Tezcan, E., Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol 18 (2003), 191–195.
38. Ciotta, L., Pagano, I., Stracquadanio, M., Di Leo, S., Andò, A., Formuso, C., Aspetti psichici del disturb disforico della fase luteale: nuove prospettive terapeutiche, il Vitex agnus castus. Nostra esperienza. Minerva Ginecol 63 (2011), 237–245.
39. Delavar, M.A., Nasiri, F., Hoseini, S.H., A double-blind placebo-controlled evaluation of Vitex agnus castus in premenstrual syndrome. J Med Plants 1 (2002), 15–20.
40. Di Pierro, F., Callegari, A., Speroni, M., Attolica, M., Fast dissolving agnus castus fruit extract for the premenstrual syndrome. A controlled clinical trial. Nutrafoods 8 (2009), 27–31.
41. He, Z., Chen, R., Zhou, Y., et al. Treatment for premenstrual syndrome with Vitex agnus castus: a prospective, randomized, multi-center placebo controlled study in China. Maturitas 63 (2009), 99–203.
42. Kaplanoğlu, M., Aban, M., Ethinyl estradiol-dropirenon versus Vitex agnus-castus extract in efficacy of the treatment of premenstrual syndrome. J Clin Anal Med, 2015 Available at: http://www.jcam.com.tr/files/JCAM-3297.pdf. Accessed March 28, 2017.
43. Lauritzen, C.H., Reuter, H.D., Repges, R., Böhnert, K.J., Schmidt, U., Treatment of premenstrual tension syndrome with Vitex agnus castus. Controlled, double-blind study versus pyridoxine. Phytomedicine 4 (1997), 183–189.
44. Mousavi, P., Zaheri, H., Najar, S., Afshari, P., Hayati, F., Effect of vitagnus on premenstrual syndrome. Iran J Obstet Gynecol Infertil 17 (2015), 1–9.
45. Onaran, Y., Kurtay, G., Binici, S., Premenstruël dönemde duygudurum. Premenstruël sendromda Vitex agnus castus ekstresi ve oral kantraseptiflerin duygudurum ϋzerindeki etkilerinin karsilastirilmasi. Kadin Dogum Dergisi 2 (2003), 73–77.
46. Pakgohar, M., Moradi, M., Jamshidi, A.H., Mehran, A., Assessment of Vitex agnus-castus L. extract effect on treatment of premenstrual syndrome. J Med Plants 8 (2009), 98–107.
47. Risoleti, E.V.I., Giuffrida, L., Iozza, I., Garofalo, O., Valenti, O., Napoli, C., Efficacia di Vitex agnus-castus nella sindroma premestruala: la nostra esperienza. G Ital Obstet Ginecol XXXIII (2011), 227–231.
48. Salehi, A., Momeni, H., Seraji, A., Comparison of the effects of Hypericum and Vitex agnus in premenstrual syndrome compared with vitamin E: a randomized clinical trial. Complementary Med J Faculty Nurs 3 (2013), 41–53.
49. Scaldarella, L.O., D'Ettore, A., Ciotola, A., Fusco, G., Ragucci, V., Colannino, G., Utilizzo di Vitex agnus castus in pazienti con syndrome premestruale, mastodinia e iperprolattinemia. G Ital Obstet Ginecol(XXX:3), 2008, 79–84.
50. Schellenberg, R., Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomized, placebo controlled study. BMJ 322 (2001), 134–137.
51. Schellenberg, R., Zimmermann, C., Drewe, J., Hoexter, G., Zahner, C., Dose-dependent efficacy of the Vitex agnus castus extract ZE 440 in patients suffering from premenstrual syndrome. Phytomedicine 19 (2012), 1325–1331.
52. Turner, S., Mills, S., A double-blind clinical trial on a herbal remedy for premenstrual syndrome: a case study. Complementary Ther Med 1 (1993), 73–77.
53. Zamani, M., Neghab, N., Torabian, S., Therapeutic effect of Vitex agnus castus in patients with premenstrual syndrome. Acta Med Iran 50 (2012), 101–106.
54. Egger, M., Dickerson, K., Smith, G.D., Problems and limitations in conducting systematic reviews. Egger, M., Smith, G.D., Altman, D.G., (eds.) Systematic reviews in health care, 2001, BMJ Publishing Group, London.
55. Gagnier, J.J., Moher, D., Boon, H., Beyene, J., Bombardier, C., Randomized controlled trials of herbal interventions underreport important details of the intervention. J Clin Epidemiol 64 (2011), 760–769.
56. Linde, K., Jonas, W.B., Melchart, D., Willich, S., The methodological quality of randomized controlled trials of homeopathy, herbal medicines and acupuncture. Int J Epidemiol 30 (2001), 526–531.
57. Moher, D., Pham, B., Jones, A., et al. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 352 (1998), 609–613.
58. Schulz, K.F., Chalmers, I., Hayes, R.J., Altman, D.G., Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273 (1995), 408–412.
59. Linde, K., Scholz, M., Ramirez, G., Clausius, N., Melchart, D., Jonas, W.B., Impact of study quality on outcome in placebo-controlled trials of homeopathy. J Clin Epidemiol 52 (1999), 631–636.
60. Pittler, M.H., Abbot, N.C., Harkness, E.F., Ernst, E., Location bias in controlled clinical trials of complementary/alternative therapies. J Clin Epidemiol 53 (2000), 485–489.
61. Ma, L., Lin, S., Chen, R., Zhang, Y., Chen, F., Wang, X., Evaluating therapeutic effect in symptoms of moderate-to-severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Aust N Z J Obstet Gynaecol 50 (2010), 189–193.
62. Ma, L., Lin, S., Chen, R., Wang, X., Treatment of moderate to severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Gynecol Endocrinol 26 (2010), 612–616.
63. Endicott, J., Nee, J., Harrison, W., Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health 9 (2006), 41–49.
64. Gagnier, J.J., Boon, H., Rochon, P., Moher, D., Barnes, J., Bombardier, C., Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol 59 (2006), 1134–1149.